NYSE:SNN - Smith & Nephew Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$32.91
▲ +0.18 (0.55%)

This chart shows the closing price for SNN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Smith & Nephew Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Smith & Nephew in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $32.91.

This chart shows the closing price for SNN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Smith & Nephew. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 2 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/29/2022UBS GroupBoost Price TargetGBX 1,200 ➝ GBX 1,295Low
3/15/2022Royal Bank of CanadaInitiated CoverageOutperformLow
3/4/2022Redburn PartnersUpgradeSell ➝ NeutralMedium
3/2/2022JPMorgan Chase & Co.Boost Price TargetGBX 1,376 ➝ GBX 1,442High
11/5/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/4/2021Berenberg BankReiterated RatingBuyLow
9/30/2021BarclaysReiterated RatingOverweightMedium
9/10/2021BarclaysReiterated RatingOverweightLow
8/17/2021Morgan StanleyReiterated RatingOverweightLow
8/2/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/1/2021BarclaysReiterated RatingOverweightLow
6/9/2021Credit Suisse GroupUpgradeNeutral ➝ OutperformLow
5/28/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
5/4/2021Berenberg BankReiterated RatingBuyMedium
5/4/2021Credit Suisse GroupReiterated RatingNeutralMedium
4/30/2021BarclaysReiterated RatingOverweightLow
3/31/2021BarclaysReiterated RatingOverweightLow
2/23/2021Berenberg BankReiterated RatingBuyLow
2/22/2021JPMorgan Chase & Co.Reiterated RatingNeutralMedium
2/22/2021Credit Suisse GroupReiterated RatingNeutralMedium
2/22/2021CommerzbankDowngradeBuy ➝ HoldLow
1/22/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
1/21/2021BarclaysReiterated RatingOverweightLow
1/20/2021Berenberg BankReiterated RatingBuyMedium
12/18/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
12/18/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$46.50Medium
12/9/2020Morgan StanleyReiterated RatingOverweightLow
12/1/2020BarclaysInitiated CoverageOverweightLow
10/30/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/31/2020Berenberg BankReiterated RatingBuyLow
7/30/2020JPMorgan Chase & Co.Reiterated RatingNeutralMedium
7/30/2020Morgan StanleyReiterated RatingOverweightHigh
7/29/2020Bank of AmericaUpgradeNeutral ➝ BuyLow
7/10/2020Berenberg BankReiterated RatingBuyLow
6/5/2020BNP ParibasDowngradeNeutral ➝ UnderperformLow
6/5/2020Exane BNP ParibasDowngradeNeutral ➝ UnderperformLow
6/4/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
5/11/2020Berenberg BankReiterated RatingBuyLow
5/7/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
5/7/2020CfraLower Price TargetHold$52.00 ➝ $42.00Low
4/14/2020CitigroupDowngradeBuy ➝ NeutralMedium
3/31/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/21/2020CfraBoost Price TargetHold$46.00 ➝ $52.00Medium
11/21/2019CitigroupInitiated CoverageBuyLow
11/12/2019Sanford C. BernsteinInitiated CoverageOutperformLow
7/23/2019Berenberg BankUpgradeHold ➝ BuyLow
2/8/2019BNP ParibasDowngradeOutperform ➝ NeutralLow
1/1/2019JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
12/10/2018Morgan StanleyUpgradeEqual Weight ➝ OverweightMedium
12/7/2018Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldMedium
10/16/2018HSBCDowngradeBuy ➝ HoldMedium
8/8/2018UBS GroupDowngradeBuy ➝ NeutralLow
5/3/2018Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellLow
4/18/2018UBS GroupUpgradeNeutral ➝ BuyLow
3/26/2018HSBCUpgradeHold ➝ BuyHigh
1/25/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
12/11/2017Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/26/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/25/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Smith & Nephew logo
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Read More

Today's Range

Now: $32.91
Low: $32.79
High: $33.03

50 Day Range

MA: $32.12
Low: $29.72
High: $33.71

52 Week Range

Now: $32.91
Low: $29.40
High: $44.47

Volume

28,705 shs

Average Volume

812,091 shs

Market Capitalization

$14.35 billion

P/E Ratio

N/A

Dividend Yield

2.77%

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Smith & Nephew?

The following Wall Street sell-side analysts have issued stock ratings on Smith & Nephew in the last twelve months: Barclays PLC, Berenberg Bank, Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Redburn Partners, Royal Bank of Canada, StockNews.com, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for SNN.

What is the current price target for Smith & Nephew?

0 Wall Street analysts have set twelve-month price targets for Smith & Nephew in the last year.
View the latest price targets for SNN.

What is the current consensus analyst rating for Smith & Nephew?

Smith & Nephew currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNN will outperform the market and that investors should add to their positions of Smith & Nephew.
View the latest ratings for SNN.

How do I contact Smith & Nephew's investor relations team?

Smith & Nephew's physical mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The medical equipment provider's listed phone number is 441923477100 and its investor relations email address is [email protected] The official website for Smith & Nephew is www.smith-nephew.com. Learn More about contacing Smith & Nephew investor relations.